Coagulation and anticoagulation in pulmonary arterial hypertension

Israel Medical Association Journal

Volumn 11, Issue 6, 2009, Pages 376-379

  Berger, Gidon ^a,b,d   Azzam, Zaher S ^b,d   Hoffman, Ron ^c,d   Yigla, Mordechai ^a,d  

^a Division of Pulmonary Medicine   (Israel)

^b Technion Israel Institute of Technology ^*  (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anticoagulation; Pulmonary arterial hypertension; Thrombosis; Thrombotic arteriopathy

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULATION; ARTERY DISEASE; BLOOD CLOTTING; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HEART RIGHT VENTRICLE FAILURE; HUMAN; LUNG ENDOTHELIUM; PERIPHERAL VASCULAR DISEASE; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW; RISK FACTOR; SURVIVAL RATE; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR RESISTANCE; VASOCONSTRICTION;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION, PULMONARY; THROMBOEMBOLISM; VASOCONSTRICTION;

EID: 69249159573     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest 2006; 130(2): 545-52.
2. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006; 28(5): 999-1004.
3. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S): 5-12S.
4. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80(5): 1198-206.
5. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70(4): 580-7.
6. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985, 60(1): 16-25.
7. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987; 10(6): 1233-8.
8. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990; 82(3): 841-7.
9. Rabinovitch M, Andrew M, Thom H, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987; 76(5): 1043-52.
10. Geggel RL, Carvalho AC, Hoyer LW, Reid LM. von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987; 135(2): 294-9.
11. Lopes AA, Maeda NY, Aiello VD, Ebaid M, Bydlowski SP. Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension. Chest 1993; 104(5): 1455-60.
12. Lopes AA, Maeda NY. Abnormal degradation of von Willebrand factor main subunit in pulmonary hypertension. Eur Respir J 1995; 8(4): 530-6.
13. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43(2): 109-42.
14. Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 1996; 110(3): 710-17.
15. Fanburg BL, Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 199; 272(5 Pt 1): L795-806.
16. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99(3): 249-54.
17. Chaouat A, Weitzenblum E, Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996; 9(2): 356-63.
18. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131(6): 1917-28.
19. Roman A, Rodes-Cabau J, Lara B, et al. Clinico-hemodynamic study and treatment of 44 patients with primary pulmonary hypertension. Med Clin (Barc) 2002; 118(20): 761-6.
20. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005; 95(2): 199-203.
21. Ogata M, Ohe M, Shirato K, Takishima T. Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn Circ J 1993; 57(1): 63-9.
22. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327(2): 76-81.
23. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112(3): 714-21.
24. Storstein O, Efskind L, Muller C, Rokseth R, Sander S. Primary pulmonary hypertension with emphasis on its etiology and treatment. Acta Med Scand 1966; 179(2): 197-212.